ENTITY

Suzhou Ribo Life Science (6938 HK)

34
Analysis
Health Care • China
Develops siRNA therapeutics for liver, cardiovascular, metabolic and renal diseases
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x